Who
Abigail L. Jenkins
Director
Company insider
Files Form 4 as: Director, Aquestive Therapeutics; President and CEO, Gamida Cell.
In numbers
- Trades disclosed
- 11
- Buys
- 1
- Sells
- 0
- Bought
- $25K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 19 Sep 2022
- Last trade
- 10 Jun 2026
- Last filed
- 12 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Jun 2026filed 12 Jun 2026 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —50,500 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —50,500 at $0.00 | filing |
| 11 Jun 2025filed 12 Jun 2025 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $143K42,000 at $3.41 | filing |
| 10 May 2024filed 13 May 2024 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —57,000 at $0.00 | filing |
| 19 Oct 2023filed 20 Oct 2023 | Gamida Celloption or derivative | SEC FORM 4 Code A | —1,000,000 at $0.00 | filing |
| 19 Oct 2023filed 20 Oct 2023 | Gamida Cell | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 19 Oct 2023filed 20 Oct 2023 | Gamida Celloption or derivative | SEC FORM 4 Code A | —217,954 at $0.00 | filing |
| 19 Oct 2023filed 20 Oct 2023 | Gamida Cell | SEC FORM 4 Code A | —109,013 at $0.00 | filing |
| 30 Sep 2022filed 4 Oct 2022 | Gamida Cell | SEC FORM 4 Bought | $25K16,129 at $1.55 | filing |
| 19 Sep 2022filed 20 Sep 2022 | Gamida Celloption or derivative | SEC FORM 4 Code A | —1,000,000 at $0.00 | filing |
| 19 Sep 2022filed 20 Sep 2022 | Gamida Cell | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
Related people
Nobody else traded the same names lately.